The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 95 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 2.6 mo · strongest signal: Exchange deficiency notice (Aug 28, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (equity line, pipe, shelf filed, warrant inducement). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
GeoVax Labs (CIK 832489) disclosed on 28 August 2026 that Nasdaq's Hearings Panel had ruled on its listing deficiencies (8-K filed 28 Aug 2026, Item 3.01) and simultaneously closed an equity-line facility and warrant-inducement transaction (8-K filed 28 Aug 2026, Item 3.02). The company reported $3.1 million cash as of 30 June 2026 against approximately $14.6 million annualized operating cash outflow, implying roughly 2.6 months of runway from that date—now 84 days stale. Outstanding share count jumped 112 percent from 3.47 million (14 May 2026) to 7.37 million (27 July 2026), and multiple filings reference reverse splits, minimum-bid deficiencies, and stockholders' equity deficiency.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 17, 2026 | ▼ Shelf filed | S-1 filed 2026-09-17 filing | 31 |
| Sep 10, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-09-10 filing | 51 |
| Sep 10, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-09-10 filing | 42 |
| Sep 10, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-09-10 filing | 32 |
| Sep 10, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-09-10 filing | 30 |
| Aug 31, 2026 | ▼ Reverse split | “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-31 filing | 30 |
| Aug 28, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-28 (accepted 16:16 ET) filing | 60 |
| Aug 28, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-08-28 filing | 58 |
| Aug 28, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-28 filing | 52 |
| Aug 28, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-28 filing | 52 |
| Aug 28, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-08-28 filing | 48 |
| Aug 28, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-28 filing | 47 |
| Aug 28, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (EX-99.1) filed 2026-08-28 filing | 43 |
| Aug 28, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-28 (accepted 16:09 ET) filing | 35 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-28 filing | 35 |
| Aug 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-08-28 filing | 35 |
| Aug 28, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-4.1) filed 2026-08-28 filing | 33 |
| Aug 28, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-10.1) filed 2026-08-28 filing | 32 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 3,473,260 (2026-05-14) -> 7,369,243 (2026-07-27), +112% filing | 40 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~2.6 months runway: liquidity $3,143,422 as of 2026-06-30, burn $14,591,532/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 40 |
SDST Stardust Power Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · JUNS JUPITER NEUROSCIENCES, INC. · screener →